NASDAQ
Royalty Pharma plc - Class A Ordinary Shares (RPRX)
♥ 643 Thanks from members
Royalty Pharma plc (RPRX) demonstrates robust top-line momentum with strong Q2 2026 performance driven by 14% royalty receipt growth and an upgraded full-year guidance, though analysts note a persistent tension between rich P/E multiples and thin GAAP net income.